Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Withdrawn 1Unknown 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 46Lymphoid 6Head & Neck 5Thoracic 4Other hematologic neoplasm 3Other 2Gynecologic 2Gastrointestinal 2Classical hematology 2Sarcoma 1Plasma cell 1Genitourinary 1CNS 1

Conditions

Anemia, Refractory, with Excess of Blasts 271Leukemia, Myeloid, Acute 258Myelodysplastic Syndromes 254Anemia 245Leukemia 228Neoplasms 211Precursor Cell Lymphoblastic Leukemia-Lymphoma 182Leukemia, Myelomonocytic, Chronic 151Multiple Myeloma 138Venous Thromboembolism 137Myeloproliferative Disorders 131Leukemia, Lymphocytic, Chronic, B-Cell 126Lymphoma 119Lymphoma, Non-Hodgkin 118Thrombocytopenia 117Hodgkin Disease 103Anemia, Aplastic 97Febrile Neutropenia 86Hematologic Neoplasms 82Anemia, Refractory 82Primary Myelofibrosis 81Lymphoma, Follicular 81Congenital Abnormalities 81Leukemia, Myeloid, Chronic-Phase 74Leukemia, Myelogenous, Chronic, BCR-ABL Positive 73Blast Crisis 72Leukemia, Myeloid, Accelerated Phase 69Lymphoma, Mantle-Cell 68Neoplasms, Plasma Cell 66Myelodysplastic-Myeloproliferative Diseases 65

Interventions

Medical Marijuana 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Chronic Pain × Classical hematology × Clear all
NCT03944447 2022-06-02

OMNI-Can

OMNI Medical Services, LLC

Phase 2 Unknown
200,000 enrolled
Classical hematology

Chronic Traumatic Encephalopathy, Brain Injuries, Traumatic, COVID-19, Acquired Immunodeficiency Syndrome, Amyotrophic Lateral Sclerosis, Anemia, Sickle Cell, Anxiety Disorders, Autistic Disorder, Bipolar Disorder, Colitis, Ulcerative, Crohn Disease, Depression, Epilepsy, Fibromyalgia, Tourette Syndrome, Glaucoma, Hepatitis C, Sleep Initiation and Maintenance Disorders, Multiple Sclerosis, Opioid-Related Disorders, Neoplasms, Parkinson Disease, Seizures, Stress Disorders, Post-Traumatic, Inflammatory Bowel Diseases, Coronavirus Infections, Severe Acute Respiratory Syndrome, Chronic Pain

NCT01206907 2012-08-17

Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects

Endo Pharmaceuticals

Phase 3 Withdrawn
Classical hematology

Anemia, Sickle Cell, Arthritis, Juvenile, Neoplasms, Chronic Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡